| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Janda Kim is a Director at SRNE. Recent filings cover 1 purchase and 4 sales. Those positions are worth an estimated $18K at current prices.
Janda Kim's largest disclosed position is in SRNE as Director, worth about $18K. The recent filings there lean toward selling, a net 52,257 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 27, 2021 | SRNE Sorrento Therapeutics, Inc. | Director | Sale+OE | 3,000 | $5.88 | $17,640.00 | -50.0% | |
| Sep 27, 2021 | SRNE Sorrento Therapeutics, Inc. | Director | Sale+OE | 42,357 | $8.02 | $339,720.08 | -93.4% | |
| Sep 13, 2021 | SRNE Sorrento Therapeutics, Inc. | Director | Sale+OE | 8,000 | $8.04 | $64,284.80 | -72.7% | |
| Apr 12, 2021 | SRNE Sorrento Therapeutics, Inc. | Director | Sale+OE | 1,900 | $6.97 | $13,250.98 | -38.8% | |
| Feb 3, 2017 | SRNE Sorrento Therapeutics, Inc. | Director | Buy | 3,000 | $5.15 | $15,450.00 | New |